Pyridazinones as selective cyclooxygenase-2 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 4, 2003, Pages 597-600

  Li, Chun Sing ^a   Brideau, Christine ^a   Chan, Chi Chung ^a   Savoie, Chantal ^a   Claveau, David ^a   Charleson, Stella ^a   Gordon, Robert ^a   Greig, Gillian ^a   Gauthier, Jacques Yves ^a   Lau, Cheuk K ^a   Riendeau, Denis ^a   Thérien, Michel ^a   Wong, Elizabeth ^a   Prasit, Petpiboon ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; PYRIDAZINONE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PAW EDEMA; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 0037293853     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01045-4     Document Type: Article

References (15)

1. Bombardier C. Am. J. Cardiol. 89(suppl):2002;3-D.
2. Dannhardt G., Kiefer W. Eur. J. Med. Chem. 36:2001;109.
3. Prasit P., Wang Z., Brideau C., Chan C.-C., Charleson S., Cromlish W., Ethier D., Evan J.F., Ford-Hutchinson A.W., Gauthier J.Y., Gordon R., Guay J., Gresser M., Kargman S., Kennedy B., Leblance Y., Léger S., Mancini J., O'Neil G.P., Ouellet M., Percival M.D., Perrier H., Riendeau D., Rodge I., Targari P., Thérien M., Vickers P., Wong E., Xu L.-J., Young R.N., Zamboni R., Boyce S., Rupniak N., Forrest M., Visco D., Patrick D. Bioorg. Med. Chem. Lett. 9:1999;1773.
4. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Doctor S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.M., Zhang Y.Y., Isakson P.C. J. Med. Chem. 40:1997;1347.
5. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Masferrer J.L., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.S., Seibert K. J. Med. Chem. 43:2000;775.
6. Li J.J., Norton M.B., Reinhard E.J., Anderson G.D., Gregory S.A., Isakson P.C., Koboldt C.M., Masferrer J.L., Perkins W.E., Seibert K., Zhang Y., Zweifel B.S., Reitz D.B. J. Med. Chem. 39:1996;1846.
7. Pinto D.J.P., Batt D.G., Pitts W.J., Petraitis J.J., Orwat M.J., Wang S., Jetter J.W., Sherk S.R., Houghton G.C., Copeland R.A., Covington M.B., Trzaskos J.M., Magolda R.L. Bioorg. Med. Chem. Lett. 9:1999;919.
8. Friesen R.W., Brideau C., Chan C.-C., Charleson S., Deschenes D., Dube D., Ethier D., Fortin T., Gauthier J.Y., Girard Y., Gordon R., Greig G., Riendeau D., Savoie C., Wang Z., Wong E., Visco D., Xu L.-J., Young R.N. Bioorg. Med. Chem. Lett. 8:1998;2777.
9. Jas G. Synthesis. 11:1991;965.
10. Kargman S., Wong E., Greig G., Falgueyret J.-P., Cromlish W., Ethier D., Yergey J., Riendeau D., Evans J., Kennedy B., Tagari P., Francis D., O'Neill G.P. Biochem. Pharmacol. 52:1996;1113.
11. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.-C. Inflamm. Res. 45:1996;68.
12. Riendeau D., Charleson S., Cromlish W., Mancini J.A., Wong E., Guay J. Can. J. Phys. Pharmacol. 75:1997;1088.
13. Chan C.-C., Black C., Boyce S., Brideau C., Ford-Hutchinson A.W., Gordon R., Guay D., Hill R., Li C.-S., Mancini J., Penneton M., Prasit P., Rasori R., Riendeau D., Roy P., Targari P., Vickers P., Wong E., Rodger I.W. J. Pharmacol. Exp. Ther. 274:1995;1531.
14. The chiral cyclopropylmethyl alcohols for 25 and 26 were prepared according to Charette's condition: Charette, A. B.; Prescott, S.; Brochu, C. J. Org. Chem. 1995, 60, 1081. Other substitutents were eithier commercially available or prepared from the corresponding olefins.
15. max=2.4 μM).